A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9470-9472
10.1182/blood-2022-159586